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Abstract
Lipid body accumulation within leukocytes is a common feature in both clinical and experimental
infectious, neoplasic and other inflammatory conditions. Here, we will review the contemporary
evidence related to the biogenesis and structure of leukocyte lipid bodies (also known as lipid
droplets) as inflammatory organelles. Studies of leukocyte lipid bodies are providing functional,
ultrastructural and protein compositional evidences that lipid bodies are not solely storage depots of
neutral lipid. Over the past years substantial progresses have been made to demonstrate that lipid
body biogenesis is a highly regulated process, that culminate in the compartmentalization of a specific
set of proteins and lipids, that place leukocyte lipid bodies as inducible cytoplasmic organelles with
roles in cell signaling and activation, regulation of lipid metabolism, membrane trafficking and
control of the synthesis and secretion of inflammatory mediators. Pertinent to the roles of lipid bodies
in inflammation and cell signaling, enzymes involved in eicosanoid synthesis are localized at lipid
bodies and lipid bodies are sites for eicosanoid generation. Collectively, lipid bodies in leukocytes
are emerging as critical regulators of different inflammatory diseases, key markers of leukocyte
activation and attractive targets for novel anti-inflammatory therapies.
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1.0 Introduction
Lipid bodies, also named lipid droplets or adiposomes, are lipid-rich organelles present in
virtually all organisms, including plants, yeast, prokaryotes and both non-mammalian and
mammalian animal cells. Although resting mammalian leukocytes contain few lipid bodies,
lipid bodies characteristically increase in numbers and prominence in cells associated with
diverse inflammatory responses, including leukocytes (e.g., macrophages, neutrophils, and
eosinophils) and other cell types (e.g., endothelial cells). Lipid body accumulation within
leukocytes is observed in both clinical and experimental infectious, neoplasic and other
inflammatory conditions, including in atherosclerosis [1,2], bacterial sepsis [3,4], acute
respiratory distress syndrome [5,6], allergic lung inflammation [7–9], arthritis [10–13], and in
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mycobacterial infections [14–16]. Lipid bodies are bound not by a classic bilayer membrane
but rather by an outer monolayer of phospholipids, which at least in some cells may have a
unique fatty acid composition [17,18]. The internal core of lipid bodies is rich in neutral lipids;
and it is likely that more complex membranous domains, often obscured by overlying neutral
lipids, are present within lipid bodies. Indeed, studies of leukocyte lipid bodies are providing
functional, ultrastructural and protein compositional evidences that lipid bodies are not solely
“bags” of neutral lipid. The presence of membranous domains within leukocyte lipid bodies is
also consonant with findings pertinent to lipid bodies in adipocytes, steroidogenic cells and
other cells, as we consider below. Although in the past the presence of lipid bodies in cells has
been largely associated with neutral lipid storage and transport, it has become clear that lipid
bodies are highly regulated, dynamic and functionally active organelles.
Lipid bodies in leukocytes and other cells compartmentalize a diverse set of proteins (Figure
1). The major structural proteins present at the surface of lipid bodies are the proteins from the
PAT family [19], including perilipin [20], adipose differentiation related protein (ADRP)
[21,22], and TIP 47 (tail-interacting protein of 47 kDa) [23]. These proteins have been
implicated in lipid body assembly and biogenesis [21,22,24,25]. By using techniques of protein
identification in subcellular lipid body-enriched fractionation combined with immunodetection
of proteins by EM or light microscopy it has been shown that lipid bodies compartmentalize
enzymes involved in the biosynthesis, transport and catabolism of lipids [1] [26–31], caveolin,
proteins of Rab family and proteins involved in vesicular transport includingVAT-1, SNAP
and VAMP [29–37], eicosanoid-forming enzymes [3,38–43], protein kinases as
phosphatidylinositide 3 kinase (PI3 kinase), mitogen-activated protein (MAP) kinases, and
protein kinase C (PKC) [26,44,45]. The regulated formation of lipid bodies, their protein and
lipid content, and their association with other intracellular organelles have established
leukocyte lipid bodies as specialized, inducible cytoplasmic domains that function as
organelles with roles in cell signaling and activation, regulation of lipid metabolism, membrane
trafficking and control of the synthesis and secretion of inflammatory mediators. Here, we will
review the contemporary evidence related to the biogenesis and structure of leukocyte lipid
bodies as inflammatory organelles. Collectively, lipid bodies in leukocytes are critical
regulators of different inflammatory diseases, key markers of leukocyte activation and
attractive targets for novel anti-inflammatory therapies.
2.0 Leukocyte lipid body biogenesis
Different from neutral lipid storing cells, leukocytes contain few lipid bodies under resting
conditions (e.g., human blood neutrophils and eosinophils contain ~ 1 and ~ 5 lipid bodies/cell
[46,47]. Of note, lipid bodies in leukocytes have often not been recognized since lipid bodies
are dissolved by common alcohol-based hematologic stains. However, rapid and well-
regulated lipid body biogenesis is triggered upon leukocyte activation by different stimuli and
pathological conditions including obesity-induced inflammation, ox-LDL- and LPS-induced
inflammation or bacterial infection. Thus increased numbers of cytoplasmic lipid bodies within
leukocytes are often associated with infectious, atherosclerotic and other inflammatory
conditions.
Hypothesized mechanisms for the biogenesis of lipid bodies in varied cells types recognize
that lipid bodies are intimately related with and likely derived from the endoplasmic reticulum
(ER)(Figure 2). The proposed models of the biogenesis of lipid bodies involve ER transfer of
lipids and proteins; however the precise mechanisms involved remain to be ascertained. Three
main models have been proposed to explain the formation of lipid bodies and their interaction
with the ER. One of the first models proposed was a “budding model” where enzymes involved
in lipid metabolism accumulate in specific domains of the ER, thus favoring neutral lipid
synthesis in these regions forming a hydrophobic neutral lipid mass between the two leaflets
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of the ER bilayer (Figure 2 A). After reaching a certain size, nascent lipid bodies loaded with
proteins lacking trans-membrane spanning domains bud off the ER into the cytoplasm that
ends up surrounded by a half-unit membrane of phospholipids directly derived from the
cytoplasmic leaflet of the ER [48–51].
An alternative second model has been proposed. Based on freeze-fracture immunogold electron
microscopy observations, Robenek and colleagues have recently suggested that formation of
lipid bodies occurs preferentially alongside, not within, the ER; and an “egg cup model” of
lipid body formation was proposed (Figure 2 B). According to this model, lipid bodies would
form within ER cups particularly enriched in ADRP clusters in the cytoplasmic leaflet of ER,
with ADRP clusters functioning to transfer lipids from ER to nascent lipid bodies [52].
Based both on studies of leukocyte lipid bodies and on findings related to lipid bodies in other
cell types, we have proposed a novel “enfolding model” of lipid body biogenesis that
accommodates membrane-associated and transmembrane spanning proteins within lipid body
cores by incorporation of multiple loops of ER membranous domains [31] (Figure 2 C).
Just as PAT proteins can localize at the peripheral delimiting membrane of lipid bodies, an
initially attractive hypothetical mechanism for cytosolic proteins (e.g., 5-lipoxygenase (5-LO),
cytosolic phospholipase A2 (cPLA2) involved in eicosanoid metabolism to function at lipid
bodies was to have these membrane-active proteins “translocate” to the peripheral membrane
of lipid bodies. Of note, however, immunogold electron microscopic localization of 5-LO
revealed 5-LO to be distributed throughout lipid bodies, which were shown to have a
“honeycomb” internal structure [39], never suggesting a ”translocated” membrane association
solely at the peripheral delimiting monolayer membrane of lipid bodies. The cyclooxygenase
(COX, prostaglandin H synthase) enzymes are integral membrane proteins [53] and have been
localized at lipid bodies in different cells and by the use of different techniques including EM
immunogold, immunolocalization in intact cells and western blotting from subcellular fractions
[3,38–40,54,55] [41–43]. Similar to the described for 5-LO, EM immunogold analysis of COX
enzymes localized these proteins throughout lipid bodies in diverse cells and not restricted to
the periphery of the lipid body. Analogously, the transmembrane spanning enzyme, leukotriene
C4 (LTC4) synthase, was localized at lipid bodies [39]. As described in detailed below,
eicosanoid-forming enzymes localized at lipid bodies retain their functional enzymatic
capacity since newly generated arachidonate-derived eicosanoids are formed at lipid bodies in
inflammatory cells [8,15,56–58]. Collectively, these findings indicated that since membrane-
associated enzymes localized and functioned at leukocyte lipid bodies there would likely be
internal membranes present within these lipid bodies.
Proteomic studies of lipid bodies isolated from the U937 macrophage cell line identified diverse
proteins, about half of which had predicted membrane insertions [31], combined with
ultrastructural observations of membranous structures within lipid bodies of U937 macrophage
cell line and human eosinophils, strongly suggested the presence of internal membranes within
leukocyte lipid bodies. Accordingly, lamellar concentrically arranged membranes have been
previously described to occur on the margins of lipid droplets that penetrated the matrix of the
droplets in acetylated LDL-stimulated macrophages [1]. The presence of membranotubular
structures have also been recognized in adipocyte lipid bodies recently by embedment-free
electron microscopy [59]. The existence of membranous structures within lipid bodies of non-
leukocytic cells could also explain how stanniocalcin and its membrane receptor are present
at lipid bodies of ovarian steroidogenic cells and adipocytes [60]. Membranes within lipid
bodies would account for the freeze-fracture immunogold electron microscopic findings that
revealed caveolin-1, an integral membrane protein, as well as TIP47 and ADRP were localized
to freeze-fractured lamellae not only at the periphery of lipid bodies but also pervading lipid
body cores [61].
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Although stores of neutral lipids that accumulate at lipid bodies can obscure the internal ER-
derived components of lipid bodies, ribosomal structures and ribosomal associated proteins
have been described in leukocyte lipid bodies [31] [62,63]. Moreover, protein analyses of
Drosophila, yeast and hepatoma lipid bodies also identified ribosomal and RNA-interacting
proteins [64–68]. Future studies will be necessary to confirm and characterize the presence of
membranous structures in the lipid body core.
The triggering process and detailed molecular mechanisms involved in lipid body biogenesis
have been intensely investigated, demonstrating that leukocyte lipid body biogenesis is a highly
regulated phenomena that has been characterized as a cell and stimuli dependent event [69]
(Table 1).
Upon stimulation the genesis of new cytoplasmic lipid bodies can be induced within
neutrophils, eosinophils, and monocytes/macrophages, as well as in other inflammation-related
cell types including endothelial and epithelial cells. Studies investigating the mechanisms of
lipid body formation in leukocytes, using physiological amounts of fatty acids or other relevant
inflammatory stimuli, demonstrated that a complex biogenic process rather than unregulated
lipid incorporation takes place in leukocytes to form new lipid bodies. Among the observation
that indicate the existence of regulated production of lipid bodies in leukocyte are: (i) while
cis-unsaturated fatty acids are potent inducers of lipid bodies, saturated fatty acids do not elicit
lipid body assembly [70,71]; (ii) non-esterifiable cis-fatty acids such as the arachidonate analog
arachidonyl trifluoromethyl ketone are able to induce formation of new lipid bodies [72]; and
(iii) stimulation with cytokines/chemokines and hormones induces receptor-mediated lipid
body biogenesis not only in vivo but even in vitro in the absence of exogenous lipids (Table
1).
Attempts to characterize the signaling pathways committed to lipid body biogenesis in
leukocytes revealed that different pathways in a stimulus-dependent fashion are activated to
trigger leukocyte lipid body biogenesis. For instance, platelet-activating factor (PAF) and PAF-
like molecules, but not lyso-PAF, acting via its G-protein-linked receptor induces lipid body
formation via downstream signaling that requires 5-LO, PKC and phospholipase C (PLC)
activation [39,40,70,73], in a mechanism that may involve an autocrine loop on CCL2
generation (Figure 3). Prostaglandin (PG)D2 – another potent leukocyte chemoattractant acting
through a G-protein-linked receptor – also directly induces biogenesis of lipid bodies in
eosinophils, but not in macrophages, even though both cell types express functional PGD2
receptors demonstrating stimulus/signaling specificity according to the cell type [9]. Of note,
other G-protein-coupled receptor agonists, including IL-8, C5a and LTB4, did not induce
leukocyte lipid body formation demonstrating the requirement of specific intracellular
signaling mechanisms in the process of lipid body biogenesis [70].
Leukocytes incubated with cytokines and chemokines even in the absence of exogenous lipids
rapidly form new cytoplasmic lipid bodies by receptor-mediated processes [40,56,58,74,75].
In human eosinophils, IL-5 alone or combined with GM-CSF, as well as immobilized IgG lead
to significant increases in lipid body numbers [40,75]. In addition, RANTES (CCL5) and
eotaxin (CCL11), eotaxin 2 (CCL24) and eotaxin 3 (CCL26) acting via their CCR3 receptors,
initiate intracellular signaling in eosinophils and basophils, but not neutrophils, to rapidly form
lipid bodies [8,56,76]. CCR3-driven lipid body biogenesis, in contrast to PAF’s effect, was
mediated by activation of MAP kinases, PI3K and tyrosine kinases, but not PKC or PLC
[56]. Likewise, in vivo administration of RANTES, eotaxin or PGD2 also induced significant
influx of eosinophils loaded with lipid bodies through their specific receptors [8,9]. Eosinophils
attracted to the site of allergic inflammatory reaction exhibited increased numbers of lipid
bodies [8,9]. Allergic inflammation induces in vivo biogenesis of lipid bodies within recruited
eosinophils in a selective manner, since it failed to activate resident mononuclear cells to form
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lipid bodies. Neutralizing antibodies to eotaxin, RANTES or the eotaxin and RANTES
receptor, CCR3, as well as a specific inhibitor of PGD2 synthesis inhibited lipid body formation
within recruited eosinophils during experimental allergic inflammatory reactions [8,9].
Therefore, allergic inflammation triggers in vivo formation of new lipid bodies within
infiltrating eosinophils, a phenomenon largely mediated by a cross-talk of eotaxin/RANTES
acting via CCR3 receptors and PGD2 acting via a receptor that has yet to be identified. A role
for eotaxin/CCR3 in lipid body biogenesis was also demonstrated to occur in infection-driven
lipid body formation in eosinophils, but not in macrophages; a mechanism that was largely
dependent on TLR2-dependent macrophage-derived eotaxin-mediated CCR3 activation [77].
Accumulation of lipid body enriched macrophage foam cells in atherosclerotic blood vessel
intima is a critical component of atherogenesis. The formation of foam cells involves complex
and multi-step mechanisms that depend on different signaling pathways regulating lipid influx,
metabolization, storage and mobilization [2,78,79]. Uncontrolled modified LDL uptake by
macrophages through scavenger receptors causes triglyceride and cholesterol loading,
followed by cholesterol esterification mediated by acyl coenzyme A:acylcholesterol
transferase and storage of cholesteryl esters (CEs) in cytoplasmic lipid bodies [2,78,79].
Different modifications of LDL, including enzymatic modification (E-LDL), acetylation (Ac-
LDL), oxidation (Ox-LDL), and glycation (AGE-LDL) have been associated to foam cell
formation in atherosclerosis [2,79–82]. Recognition and activation of scavenger receptors,
mostly CD36, by modified LDL play major roles in lipid accumulation in macrophages [83–
87]. In addition, different lipid-derived molecules generated in the process of LDL oxidation
are involved in lipid body formation including PAF-like molecules [73,88], sterol ester [89],
oxysterols [90], 1-palmitoyl-2-(5′-oxovaleroyl)-sn-glycero-3-phosphocholine [91], azelaoyl-
phosphatidylcholine [73].
Adipocytokines including leptin and resistin were also shown to modulate lipid body formation
in macrophages and may participate in the mechanisms of foam cell formation [92–94]. In
addition, current studies have demonstrated that monocyte chemoattractant protein (MCP-1/
CCL2), a key endogenous mediator involved in the pathogenesis of macrophage-driven
inflammation such as atherosclerosis and sepsis, is centrally involved in the regulation of
macrophage lipid body biogenesis in oxidized LDL-and LPS-induced inflammation as well as
in experimental sepsis [58,88], Silva, submitted). MCP-1-driven lipid body accumulation is a
highly regulated phenomenon, requisitely dependent of MCP-1 receptor, CCR2, and
downstream signaling through MAP-and PI3-kinases [58]. Moreover, MCP-1-elicited lipid
body assembly and protein compartmentalization was demonstrated to depend on a functional
microtubule network. Accordingly, lipid bodies are enmeshed in a cytoskeleton network in
several cell types [31,95–97], and lipid body-cytoskeleton interaction were shown also to have
roles in lipid body motility [36], rapid relocation upon cell activation with chemotactic agents
[56], and lipid body fusion and growth [98] (Figure 3).
Whether inflammation-driven lipid body formation depends on either a direct effect of
endogenous mediators present at the site of inflammatory reaction or is triggered by cellular
migration and/or phagocytosis dependent mechanisms at the inflammatory site has been
investigated. Attempts to answer the role of cell migration – a multi-step process that involves
rolling, adhesion, transmigration and chemotaxis – to lipid body biogenesis indicate that
migration may modulate, but is not requisitely involved in leukocyte lipid body formation
during inflammation. Increased lipid body biogenesis may be dissociated from cell recruitment
as (i) resident macrophages have significantly increased lipid body numbers within 6 hours of
LPS stimulation when there is no concurrent increase in the number of macrophages at the
inflammatory site [3]; (ii) while in vivo infection with Mycobacterium bovis BCG induced both
migration and lipid body formation within recruited leukocytes, infection with non-pathogenic
Mycobacterium smegmatis although inducing an intense leukocyte recruitment, failed to
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trigger the process of lipid body biogenesis [15,69]; and (iii) lipid body numbers are drastically
increased in blood leukocytes from septic patients or rats with Chagas disease when compared
to blood leukocytes from healthy subjects [3,99], indicating that leukocytes that did not undergo
migration can also form new lipid bodies in vivo during a systemic inflammatory disease. The
lack of correlation between phagocytosis and lipid body formation was also experimentally
demonstrated. By comparisons of percentages of infected cells and of cells with increased lipid
body numbers after BCG infection, it was demonstrated that more than 95% of cells had highly
increased lipid body numbers, while less than 30% of the cells were infected. In addition,
macrophage uptake of latex beads, Bacillus subtillis, and nonpathogenic mycobacteria M.
smegmatis was not able to trigger lipid body formation [15]. Together, these findings indicate
that phagocytosis is neither sufficient nor essential for pathogen-induced lipid body formation,
and may suggest that transfer of bacterial lipids to non- infected bystander cells and/or
cytokines and other inflammatory factors generated at infection foci might contribute to lipid
body formations in leukocytes. Accordingly, components from bacterial cell walls, including
E. coli LPS and M. bovis BCG- or M. tuberculosis-derived lipoarabinomannan (LAM) can
mimic the pathogen and induce lipid body accumulation in a time- and dose-dependent manner
[3,15,58]. Pattern recognition receptors play major roles in regulating lipid body biogenesis
during infection [100]. LPS-induced lipid body formation in macrophages was demonstrated
to occur through a mechanism largely dependent on TLR-4 in cooperation with CD14 and
CD11b/CD18 [3]. Both BCG and the purified cell component, LAM, failed to induce lipid
body formation in macrophages and other leukocytes from TLR2-deficient mice, although lipid
body formation was not modified in TLR4 deficient animals, suggesting an important role for
TLR2 in this phenomenon [15,77]. Similarly, Chlamydia pneumonia, a pathogen that has been
implicated in human and murine macrophage foam cell formation, a hallmark of early
atherosclerosis, express a variety of ligands that could serve as potential TLR ligands and
chlamydial infection induced macrophage lipid body formation in the presence of LDL was
shown to occur through TLR2-, but not TLR4-, dependent mechanisms [101]. Interestingly,
stimulation of macrophages in vitro with zymosan, a potent TLR2 activating agent, failed to
induce lipid body formation, thus suggesting that although TLR2 activation is essential for
mycobacteria-induced lipid body formation, it is not sufficient to trigger pathways of lipid body
formation [15] and may involve TLR2 co-factors.
The biogenesis of lipid bodies in leukocytes is a rapidly regulated phenomenon therefore,
raising the question whether lipid body formation depends on new protein synthesis. Of note,
although maximum PAF-induced lipid body formation occurs within 1 hour, pretreatment of
leukocytes with protein synthesis inhibitors partially inhibited PAF-, but not eotaxin- and
RANTES-induced lipid body formation, thus indicating that, depending on the stimulus,
induction of lipid bodies requires protein synthesis and it is likely that the transcription of early
response genes is activated [3,13,39,56,70]. A role for Peroxisome Proliferator-Activated
Receptors (PPARs), members of the nuclear receptor gene family that function in ligand-
activated transcription, on macrophage differentiation on lipid accumulating cells has been
demonstrated [102,103]. Indeed, specific PPARγ ligands, significantly potentiate lipid body
formation induced by ox-LDL, PAF-like agonists and G-CSF, suggesting that PPARs have a
role in regulating leukocyte lipid body formation [73,104]. Accordingly, PPAR are capable of
modulating ADRP gene transcription in different cells including macrophages [105,106].
Interestingly, leptin-induced lipid body accumulation in macrophages in vivo or in vitro is
accompanied by increased levels of ADRP [93], demonstrating that leptin directly regulates
the increase in ADRP cell content and accumulation of lipids within ADRP-enriched lipid
bodies in macrophages and may have a role in foam cell formation. Increased ADRP expression
by itself has been shown to be directly related to the enhanced capacity of neutral lipid storage,
as ADRP promotes triglycerides and cholesterol storage and reduces cholesterol efflux [107].
ADRP may act also as a nucleation center for the assembly of lipids to form nascent lipid bodies
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and to enhance droplet stability upon lipolytic conditions [108,109]. New findings are starting
to unveil an important role for translational control by mTOR in the biogenic mechanisms of
lipid bodies. We have recently established that mTOR activity is an important intracellular
player in the regulation of macrophage lipid metabolism and inflammatory mediator production
induced by leptin [93]. Leptin-induced ADRP-enriched lipid bodies were drastically reduced
by the treatment with the mTOR inhibitor rapamycin. Taken together with the ability of leptin
to induce the time- and dose-dependent P70S6K and 4EBP1 phosphorylation in a rapamycin-
sensitive way, these data strongly suggest that leptin-induced increased cellular levels of ADRP
depend on translational control through mTOR-dependent activation [93,94] (Figure 3).
Similarly, mTOR-dependent translational control of ADRP expression has also been observed
in adipocytes stimulated with conjugated linoleic acid [110]. Of note, mTOR pathway
integrates signals from nutrients, energy status and growth factors to regulate many processes,
including cell growth, proliferation, autophagy and metabolism [111]. Indeed, rapamycin
treatment is a potent inducer of autophagy. The interplay between lipid bodies and autophagy
are starting to be investigated [112,113]. Those studies suggest that lipid bodies are in close
contact and act in concert with the proteasomal and autophagic pathways of protein degradation
[112,113]. Intriguingly, starvation-induced autophagy in Balb-c mouse macrophages is
accompanied by increases in lipid body numbers and facilitation of Leishmania parasite growth
[114].
3.0 Lipid Body Functions in Inflammation
The compartmentalization of signaling components within discrete and dynamic sites in the
cell is critical for specificity and efficiency of enzymatic reactions of phosphorylation, enzyme
activation and function [115]. Spatio-temporal regulation of the different enzymes involved in
cell signaling is an area of increasingly interest. Accumulating evidence has placed lipid bodies
as key organelles involved in the regulation of cell signaling in inflammatory cells [69,116].
Over the past years substantial progresses have been made demonstrating that enzymes
involved in eicosanoid syntheses localize at lipid bodies and lipid bodies are major sites for
eicosanoid generation. Moreover, other inflammatory-relevant functions for lipid bodies have
been hypothesized based on their composition and will be also discussed below.
3.1 Lipid bodies are specialized locales of eicosanoid synthesis
Eicosanoids are a family of arachidonic acid-derived signaling lipids that control important
cellular processes, including cell proliferation, apoptosis, metabolism and migration [117,
118]. Thus, eicosanoids have key roles in physiological and pathological conditions such as
tissue homeostasis, inflammation and cancer [117,118]. Analyses of lipid bodies in different
cell types and different stimulatory conditions have demonstrated that lipid bodies are
particularly active sites for the metabolism of arachidonyl lipids. Electron microscopic
autoradiographic observations demonstrated that exogenous radiolabbelled arachidonate was
incorporated prominently in lipid bodies of eosinophils, neutrophils, mast cells, macrophages
and epithelial cells [46,119–122]. Lipid bodies obtained by subcellular fractionation provided
direct evidence that these organelles are stores of esterified arachidonate. In eosinophils,
arachidonate was incorporated predominantly in the phospholipid pool [120]; whereas
arachidonic acid-containing neutral lipids appear to be the major store of arachidonic acid in
monocyte/macrophages [5,26]. Free arachidonic acid is an extremely reactive molecule that
functions in cell signaling acting as an intracellular second messenger, as a paracrine mediator
of cell activation and as a substrate for enzymatic conversion into eicosanoids [117,123].
Although, negligible amounts of free AA were identified in lipid bodies, different enzymes
involved in arachidonic acid metabolism as well proteins involved in arachidonic acid transport
were characterized in lipid bodies, thus providing strong evidence for a major role for lipid
bodies in arachidonic acid metabolism. If lipid bodies are indeed involved in arachidonic acid
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signaling and eicosanoid mediator formation, then the arachidonic acid present in these lipid-
rich organelles must be released by phospholipases; and the free arachidonate must have access
to eicosanoid-forming enzymes. cPLA2 specifically hydrolyzes arachidonic acid from the sn-2
position of glycerophospholipids and thus serves as the rate-limiting enzyme in the formation
of eicosanoids and platelet-activating factor [124]. cPLA2 and its activating protein kinases,
ERK1 and ERK2, was demonstrated to co-localize at lipid bodies [26]. cPLA2α localizes to
lipid bodies in cells responding to a wide range of stimuli, including arachidonic acid [125],
Moreira, submitted). Moreover, high cPLA2 specific activity was present in the lipid body
fraction detected by measuring the release of radiolabeled arachidonic acid from the sn-2
position of 1-palmitoyl-2-[14C] arachidonyl phosphatidylcholine [26]. A large proportion of
leukocyte arachidonate is stored in triglyceride pools in lipid bodies [5,26,126]. However the
function and utilization of this arachidonic acid triglyceride pool has been elusive. The
identification of triglyceride lipase and its activator CGI-58 within lipid bodies [29–31] opens
the perspective that arachidonate from triglycerides within lipid bodies could be used as a
storage pool to replenish, upon transfer, lipid body arachidonyl-phospholipids, from which
regulated activation of cPLA2 would provide arachidonate for local eicosanoid synthesis.
Proteins potentially involved in arachidonic acid transport were also shown to localize within
lipid bodies. S100A9, a protein involved in the transport of arachidonate and in the shuttle of
unsaturated fatty acids to membranes [127,128], was recently identified in the proteomic
analysis of leukocyte lipid bodies [31]. S100A9 might participate in arachidonate-derived
eicosanoid formation within leukocyte lipid bodies. Lipid bodies in neutrophils have also been
shown to rapidly move and interact with phagosomes, potentially delivering lipid body-derived
arachidonate to activate phagosomal NADPH oxidase [129,130].
Intracellular compartmentalization of eicosanoid synthesis within leukocytes has emerged as
a key feature that regulates the amount and may also regulate the eicosanoid produced. In
support of this, significant correlations between lipid body formation and enhanced generation
of both 5-LO- and COX-derived eicosanoids (LTC4, LTB4 and PGE2) were observed, thus
indicating that lipid body numbers in leukocytes would result in enhanced capacity of
eicosanoid production by leukocytes (Table 2). Indeed, stimuli known to prime leukocytes to
induce eicosanoid generation, including PKC activators, arachidonate and PAF, are also active
in stimulating lipid body formation [3,13,39,70,71]. Accordingly, others and we observed a
significant correlation between lipid body formation and enhanced generation of both LO- and
COX-derived eicosanoids in vitro [13,39,40,58,70,75,131] as well as in vivo [3,8,73,88,93,
99].
To support a role for lipid bodies in AA metabolism the location of key eicosanoid-forming
enzymes were investigated by using a variety of techniques, cells and stimulatory conditions.
The major enzymes, 5-LO, 15-LO, FLAP and COX, involved in the enzymatic conversion of
AA into eicosanoids were shown by immunocytochemistry/immunofluorescence,
ultrastructural postembedding immunogold EM and/or western blotting from subcellular
fractions to localize within lipid bodies stimulated in vitro [38–40,54,57] or obtained from in
vivo inflammatory responses [3,8,15,93] (Figure 4). Moreover, even the down-stream
membrane spanning enzymes involved in LTC4 production – LTC4 synthase –, and PGE2
production –PGE2 synthase- have been found at lipid bodies [39,42,57].
Overall, lipid bodies compartmentalize the substrate and the entire enzymatic machinery for
eicosanoid synthesis. It was recently established that successful eicosanoid production is not
merely determined by AA and eicosanoid-forming enzymes availability, but requires
sequential interactions between over 6 specific biosynthetic proteins acting in cascade, and
may involve very unique spatial interactions. Therefore, just by detecting eicosanoid-forming
enzymes within lipid bodies one cannot assure that these organelles are indeed accountable for
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the efficient and enhanced eicosanoid synthesis observed during inflammatory responses. That
lipid bodies can properly arrange enzymatic complexes with successful eicosanoid-forming
properties and, therefore, function as specialized domains for focal eicosanoid generation has
been documented by the direct intracellular localizations of newly formed eicosanoids. Direct
assessment of specific intracellular sites of eicosanoid synthesis has been elusive, as those lipid
mediators are newly formed, not stored and often rapidly released upon cell stimulation. By
means of a strategy to covalently cross-link, capture and localize newly formed eicosanoids at
their sites of synthesis, we demonstrated that lipid bodies are major intracellular locales for the
activation-elicited formation of LTC4 in eosinophils [8,56,132], LTB4 in neutrophils and
macrophages [58] and PGE2 in macrophages and epithelial cells [57,122,133] (Figure 4).
Importantly, eicosanoid formation within lipid bodies is not restricted to leukocytes or to
inflammatory conditions. Cells that produce high quantities of eicosanoids under physiological
conditions, including granulosa cells of periovulatory follicles involved in the production of
PGE2 which is necessary for normal ovulation [134], luteal steroid-producing and interstitial
cells involved in regression of the corpus luteum [43], and fetal membranes with advancing
gestation and labor [42,135], were demonstrated to exhibit high numbers of lipid bodies
containing eicosanoid synthetizing enzymes. Moreover, endothelial and epithelial cells
involved in pathological conditions such as in cancer, hypoxia and during infections were
shown to contain increased numbers of eicosanoid-synthesizing lipid bodies [38,54,55,57,
122,136].
The roles of lipid body-derived eicosanoids may vary depending on leukocyte type, stimulus
and inflammatory conditions controlling the eicosanoid synthesis. Eicosanoids synthesized at
lipid body sites may function as intracellular and extracellular mediators. For instance, LTC4
synthesized at lipid bodies within eosinophils following in vitro eotaxin stimulation were
shown to have a novel function as an intracrine mediator regulating IL-4 secretion from
eosinophils [137]. On the other hand, LTC4 synthesized within eosinophil lipid bodies during
in vivo allergic inflammation has paracrine activities, inasmuch as LTC4 was released from
eosinophils and was able to activate other cells present in the inflammatory site [8,9].
3.2 Storage of Cytokines
Another group of inflammatory mediators that were identified to localize within lipid bodies
are cytokines — a family of glycoproteins with diverse biological activities involved in cell
growth, inflammation, immunity, differentiation and repair. Cytokines and chemokines are
produced and secreted by a variety of activated leukocytes including macrophages, neutrophils,
mast cells, basophils and eosinophils. In addition to their ability to synthesize new cytokine
proteins, leukocytes also contain cytokines as stored, preformed pools that can be found within
a variety of cellular compartments, including granules, vesicles and lipid bodies [138]. Tumor
necrosis factor-alpha (TNF-α) was the first cytokine found within lipid bodies, detected
throughout cytoplasmic lipid bodies cores by immune gold EM of different cell types present
in colonic Crohn’s disease biopsies, including infiltrating neutrophils, macrophages and
eosinophils [139]. TNF-α was also found at lipid bodies of circulating monocytes and
neutrophils of septic patients and murine macrophages and neutrophils of experimentally
induced sepsis [3]. Cytoplasmic lipid bodies in isolated human lung mast cells contain the basic
fibroblast growth factor (bFGF), which also is present in the mast cell secretory granules
[140]. Close associations of bFGF-containing lipid bodies and smooth ER, ribosomes and
nuclei were observed in human lung mast cells, which may suggest a non-classical synthetic/
secretory- storage pathway for bFGF in human mast cells [140].
In human eosinophils, TNF-α [139] and the lymphocyte chemoattractants RANTES and IL-16
[141] have been detected at lipid bodies. Notably, suggestive interactions between lipid bodies
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and secretory vesicles involved in cytokine release in these cells termed eosinophil sombrero
vesicles (EoSVs) [142,143], are frequently identified in the cytoplasm and raises a potential
role for lipid bodies in vesicular trafficking (Melo, Dvorak and Weller, unpublished data;
[69].
If lipid bodies represent additional subcellular storage compartments for cytokines within
leukocytes, routes for cytokine-mediated secretion may exist and still need to be characterized.
Alternatively, lipid body-stored cytokines may function as intracrine signaling mediators. In
leukocytes, stimulus-coupled release of cytokine containing granule and/or vesicles to the cell
surface for release is largely dependent on fusion mediated by the SNAREs that are present on
granules/secretory vesicles and on the plasma membrane [144]. The internal membranes and
cytoplasmic domains within lipid bodies may have candidate roles in the processes of vesicular
transport, membrane fusion and protein secretion. Interestingly, a number of proteins likely
involved in vesicular trafficking were shown to localize at lipid bodies in macrophages,
including VAT-1 (synaptic vesicle membrane protein) homologue, SNAP29 (vesicle
membrane fusion protein), transmembrane traffic protein, GTP binding protein SAR 1a, and
Rap-1a [31]. The presence of members of the vesicular trafficking system within lipid bodies
was recently confirmed by Bostrom et al, who showed the presence of NSF (N-ethylmaleimide-
sensitivefactor), α-SNAP (soluble NSF attachment protein) and the SNARE s (SNAP
receptors), SNAP23 (synaptosomal-associated protein of 23 kDa), syntaxin-5 and VAMP4
(vesicle-associated membrane protein 4) at lipid bodies and demonstrated that SNARE proteins
have roles in lipid body fusion processes in the cell [37]. Future studies will be necessary to
characterize the regulation and function of cytokines within lipid bodies.
3.3 Compartmentalization of cell signaling
The presence of a variety of kinases within leukocyte lipid bodies has implicated this organelle
as a cytoplasmic domain with compartmentalizing roles in intracellular signaling. The MAP
kinases (also known as extracellular signal-regulated kinases – ERKs), as well as PKC and
PI3K are key enzymes implicated in intracellular signaling of diverse cellular responses that
can be found within leukocyte lipid bodies [26,44,45]. MAP kinase ERK1, ERK2 and p38 are
key enzymes in the activation of cPLA2, the enzyme that specifically hydrolyzes arachidonic
acid from the sn-2 position of glycerophospholipids. Yu et al. demonstrated the co-
compartmentalization of several MAP kinases and cPLA2 at arachidonate enriched-lipid
bodies [26]. The substantial association of cPLA2 activators ERK1 and ERK2 with lipid bodies
may serve to ensure rapid phosphorylation of cPLA2 on lipid bodies in response to extracellular
stimuli.
PI3K regulatory and catalytic subunits were also localized to lipid bodies by
immunocytochemistry and/or immunoblotting and enzyme assays of subcellular fractions of
isolated lipid bodies from monocyte/macrophage and polymorphonuclear leukocytes [44]. In
addition, co-immunoprecipitation studies demonstrated PI3K to be physically associated with
phosphorylated Lyn kinase in lipid bodies induced to form in human polymorphonuclear
leukocytes [44]. Although functional studies still need to be carried out to characterize the
actual roles of lipid body-resident kinases, accumulating evidence indicate that kinase-
mediated signaling is active within cytoplasmic lipid bodies in leukocytes.
Novel findings are starting to reveal functions of leukocyte lipid bodies as sites of ribosomal
translation and de novo protein synthesis with potential implications for the regulation of
inflammation-related proteins. EM analyses of leukocyte lipid bodies demonstrated the
presence of ribosomes or particles resembling ribosomal subunits. Moreover, ribosomes or
ribosome subunit-like particles were present within the lipid-rich cores and/or attached to LB
borders of LBs in monocyte cell line U937 and in human neutrophils and eosinophils [31].
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That lipid bodies may be sites of ribosomal function is supported by the demonstration of 3H-
uridine accumulation in lipid bodies and poly (A) mRNA detection in lipid bodies by in situ
hybridization [62,63]. Moreover, proteomic analyses of purified lipid body fractions of U937
identified several ribosomal subunit proteins as well as translation initiation factors in isolated
lipid bodies [31]. Likewise, proteomic analyses of lipid bodies from hepatitis C virus core
protein expressing hepatoma cell have identified ribosomal and RNA-interacting (DEAD box)
proteins [66]. Does ribosomal localization within lipid bodies translate into compartmentalized
protein synthesis at lipid bodies? Are there specific transcripts that are regulated within lipid
bodies? Future investigations are necessary to characterize the roles of lipid bodies in the
regulation of local protein synthesis during inflammation.
4.0 Involvement of lipid bodies in inflammatory disorders and potential as
targets for therapeutic intervention
Lipid bodies may function as specialized intracellular sites of signaling within leukocytes
engaged in inflammatory process ranging from allergy, to infections, to cancer and
atherosclerosis. Inducible mechanisms that enhance eicosanoid production are attractive
targets for anti-inflammatory pharmacological intervention. Although no specific lipid body
inhibitor has been described so far, different classes of drugs as well as gene knockdown of
PAT proteins have been demonstrated to inhibit lipid body formation. The hypothesis of lipid
body inhibition as target for anti-inflammatory therapy has been tested in different model
systems.
Aspirin and selected other non-steroidal anti-inflammatory drugs (NSAIDs) inhibited lipid
body formation in vivo and in vitro [13,145,146]. This inhibition occurs through COX-
independent mechanisms, because cis-unsaturated fatty acid-induced formation of new lipid
bodies in macrophages from COX-1- and COX-2-deficient mice was not impaired; and
NSAIDs, including aspirin, sodium salicylate, indomethacin, and NS-398, inhibited lipid body
formation equally in macrophages from wild-type and COX-1- or COX-2-deficient mice [13,
145]. Pertinent to understanding the anti-inflammatory activities of aspirin, aspirin and
NSAIDs, by a COX-independent mechanism, inhibited the early induction by cis-fatty acids
of both lipid body formation and priming for enhanced eicosanoid formation in leukocytes,
including notably inhibiting enhanced 5-LO pathway-mediated leukotriene generation [13].
These findings extend the anti-inflammatory capacities of aspirin and NSAIDs to include
suppression of more than COX pathway-derived eicosanoids. On the other hand, in more
complex stimulatory conditions, such as allergic inflammatory reactions, both COX
independent and dependent processes appear to intermediate activation of lipid body-regulated
lipoxygenase pathway [9].
Lipoxygenase pathway-derived cys-LTs (LTC4, LTD4, LTE4) have key roles in the
pathogenesis of allergic inflammatory diseases, such as asthma [147]. In fact, pharmacological
blockage of cys-LTs synthesis/effects has been proved to be beneficial in controlling aspects
of allergic pulmonary inflammation [148–150]. Therefore, one can hypothesize that the
inhibitory impact on the biogenesis or function of allergen-driven lipid bodies - the cysLTs-
synthesizing compartments in vivo [8,9] - may have additional therapeutic effects.
Approaches to inhibit lipid accumulation in macrophage foam cells may be of therapeutic value
in preventing atherosclerosis and has been recently reviewed elsewhere [78]. Different
strategies to inhibit lipid body formation have been tested to address the role of macrophage
lipid bodies as targets for therapeutic intervention in atherosclerosis. ADRP expression
facilitates foam cell formation induced by modified lipoproteins in mouse macrophages in
vitro, conversely ADRP gene inactivation in apolipoprotein E-deficient mice reduces the
number of lipid bodies in foam cells in atherosclerotic lesions and protects the mice against
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atherosclerosis [151]. ACAT inhibitors including the fungal-derived cyclodepsipeptides
showed potent inhibitory activity of lipid body accumulation in mouse peritoneal macrophages
and exerted antiatherogenic activity in both low-density lipoprotein receptor- and
apolipoprotein E-knockout mice [152].
The enhanced capacity of macrophages to generate PGE2 in the course of mycobacterial
infection due to increased lipid body formation and compartmentalization of stimulated local
eicosanoid production within lipid bodies may contribute to the mechanisms that intracellular
pathogens have evolved to survive in host cells and suggest inhibition of lipid body function
as a target for pharmacological intervention in intracellular pathogen infection. Indeed,
PGE2 inhibits the Th1 type response and TNF–α and NO production [153,154]. In order to
characterize the roles of NSAID-induced inhibition of formation of lipid bodies and PGE2 on
mycobacterial host response, the levels of one pro-inflammatory (TNF-α) and one anti-
inflammatory cytokine (IL-10) were investigated. Accordingly, treatment with aspirin or NS
398 lead to an enhancement of TNF-α production and a drastic reduction in IL-10 generation
induced by BCG-infection, that paralleled the inhibitory effect of these NSAIDs on PGE2 and
lipid body formation [15]. Similar immunomodulation of mycobacterial infection was obtained
with lipid body inhibition by C75, a fatty acid synthase inhibitor [155]. Interestingly, although
C75 is not a COX inhibitor, it significantly inhibited mycobacterial induced lipid body-derived
PGE2 and enhanced TNF-α production. These data suggest that lipid body induction and lipid
body-derived PGE2 down-modulate the macrophage response by inhibiting BCG-induced
TNF-α production (key cytokine in mediating macrophage-induced mycobacterial killing) and
increasing the levels of the anti-inflammatory cytokine IL-10 which may favor intracellular
pathogen growth. Thus, inhibition of lipid body formation may be of value as a co-treatment
in intracellular pathogen infections.
A role for lipid bodies as a potential target to generate new drugs for cancer treatment has been
recently suggested [57]. Colonic adenocarcinoma cells contain increased numbers of lipid
bodies with documented PGE2 synthase localization and focal PGE2 synthesis.. Inhibition of
lipid body formation by either aspirin or a fatty acid synthase inhibitor correlated with both
inhibition of PGE2 generation and cell proliferation in CACO-2 and IEC-6 H-rasV12 cells
[57]. The inhibition of lipid body generation may affect the subcellular compartmentalization
of COX-2 and in consequence inhibit the enhanced prostaglandin synthesis that is related to
the pathogenesis of colon cancer.
Future studies will be necessary to characterize the role of lipid bodies as targets for therapeutic
intervention in diseases that progress with increased lipid body accumulation as in
atherosclerosis, hepatic steatosis, cancer and inflammation. That to include further safety
characterization of lipid body inhibition as lipid accumulation within lipid bodies may act as
protective mechanisms in lipid homeostasis against cellular lipotoxicity. Moreover, the
development of selective lipid body inhibitors is in need.
6.0 Concluding Remarks
Major advances in the understanding of the cellular and molecular mechanisms regulating
leukocyte lipid body biogenesis and functions were achieved in recent years. Our contemporary
view of lipid bodies places this organelle as critical regulators of different inflammatory and
infectious diseases and key markers of leukocyte activation. Notably, leukocyte lipid body
biogenesis is highly regulated and is cell and stimuli specific. Studies of lipid body structural
features have revealed a much more complex structure then initially anticipated that beside
lipids includes a diverse array of proteins that may vary according to the cell type and cellular
activation state and thus may determine different cellular functions for lipid bodies. Moreover,
internal membranes and ribosomes were identified within leukocyte lipid bodies adding to the
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system complexity. In leukocytes and other cells, it have been established that lipid bodies are
specialized, inducible cytoplasmic domains that have central roles to control the synthesis and
secretion of inflammatory mediators. However, for an organelle centrally involved in cellular
lipid balance and cellular signaling, our current understanding of its biogenesis, dynamics,
heterogeneity and function in different cellular systems are still very limited. Critical open
questions remain about the formation and functions of lipid bodies not only to understand
normal leukocyte function but also in several inflammatory-related diseases. In conclusion,
recent studies place lipid bodies as multifunctional organelles with key function in lipid storage
and cell signaling in inflammation and as such are emerging as attractive target candidate for
therapeutic intervention.
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leukotriene
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Figure 1.
Lipid body-associated proteins
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Figure 2. Biogenesis and structure of lipid bodies
Lipid body biogenesis involves ER-dependent mechanisms of lipid and protein transference.
Three main models have been proposed: (A) formation of a neutral lipid mass synthesized by
ER enzymes that is deposited in a hydrophobic domain between the two leaflets of the ER
membrane; followed by budding off of this lipid structure into the cytoplasm that ends up
surrounded by a half-unit membrane of phospholipids directly derived from the cytoplasmic
leaflet of the ER; (B) formation of lipid bodies at ADRP-enriched clusters in the cytoplasmic
leaflet of ER with the transference of lipids from ER to nascent lipid bodies within ER cups,
rather than between ER leaflets; (C) formation of lipid bodies by incorporation of multiple
loops of ER membranous domains, with accumulation of neutral lipids among the membranes
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within lipid bodies. As detailed in C, ultrastructural and proteomic studies of lipid bodies
isolated from leukocytes revealed internal membranes within these leukocyte lipid bodies and
identified diverse proteins, about half of which had predicted membrane insertions [31]. In
addition, ribosome and ribosomal-associated proteins have also been identified within lipid
bodies.
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Figure 3. Schematic representation of the molecular mechanisms regulating leukocyte lipid body
biogenesis and function
Lipid body formation in leukocytes is a highly regulated process that involves receptor-
mediated signaling. Lipid body formed during inflammatory stimulation culminates in the
compartmentalization of lipids and proteins and function as specialized domains involved in
eicosanoid synthesis.
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Figure 4. Leukocyte lipid bodies are intracellular locales for eicosanoid synthesis in inflammation
Leukotriene forming enzymes 5-LO (A) and FLAP (B) are localized at leukocyte lipid bodies
obtained from in vivo LPS-stimulated animals. In A, colocalization of 5-LO at ADRP-labeled
In C and D, Newly formed eicosanoids were immobilized at its site of synthesis by cross-
linking of the lipids to adjacent proteins using 1-ethyl-3-(3-dimethylamino-propyl)
carbodiimide (EDAC). LTB4 were identified by using anti-LTB4 and revealed with Cy2-
labeled anti-rabbit IgG. In C, Images show LTB4 immuno-reactive lipid bodies (as identified
by anti-ADRP) of peritoneal macrophages. In D, Leukocytes from in vivo vehicle- (right
panel) or LPS-stimulated animals (middle panel) were immunolabeled for newly formed
LTB4 after LPS stimulation. LPS-stimulated animals were treated with the 5-LO inhibitor
zileuton before incubation with EDAC (left panel), demonstrating that eicosanoid production
at lipid bodies is a regulated and enzymatic-dependent process. Images show that LTB4
immunolabeling has a punctate cytoplasmic pattern that is absent in nonstimulated cells,
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inducible by LPS, and sensitive to zileuton (Part C and D were reproduced with permission
from [58] Copyright 2007 The American Association of Immunologists, Inc.).
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Table 1
Leukocyte lipid body formation is cell- and stimuli-dependent
Stimuli Cell Type References
Fatty Acids
Unsaturated fatty acids, but not saturated fatty
acids
Neutrophils, eosinophils, monocyte/macrophages 13,71,131
Lipoproteins
Ac-LDL/E-LDL/AGE-LDL/Ox-LDL, but not
native LDL
Macrophages, but not neutrophils 1,2,73,79–82,102
Pathogen-derived molecules
LPS/LAM Macrophages, neutrophils 3,15
Lipid mediators
PAF, but not lysoPAF Neutrophils, eosinophils, macrophages 39,40,70,73
5-HETE Neutrophils 70
PGD2 Eosinophils but not macrophages 9
Hormones
Leptin, resistin Macrophages 92,93
Cytokines/Growth factors
IL-5, GM-csf, IL-16 Eosinophils 40,75,76
Chemokines
CCL5/CCL11/CCL24/CCL26 Eosinophils 56,74
CCL2 Macrophages 58
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